MicroRNA-30 inhibits the growth of human ovarian cancer cells by suppressing RAB32 expression
Open Access
- 5 January 2022
- journal article
- research article
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
Abstract
MicroRNAs (miRs) exhibit the potential to act as therapeutic targets for the management of human cancers including ovarian cancer. The role of microRNA-30 (miR-30) via modulation of RAB32 expression has not been studied in ovarian cancer. Consistently, the present study was designed to characterize the molecular role of miR-30/RAB32 axis in human ovarian cancer. Cell viability was determined by MTT assay. Expression analysis was carried out by qRT-PCR. Dual luciferase assay was used to confirm the interaction between miR-30 and RAB32. Scratch-heal and transwell chamber assays were used to monitor the cell migration and invasion. Western blotting and immunofluorescence assays were used to determine the protein expression. The results revealed significant (p < 0.05) downregulation of miR-30 in human ovarian cancer cell lines. Overexpression of miR-30 in ovarian SK-OV-3 and A2780 cancer cells significantly (p < 0.05) inhibited their proliferation. Besides, ovarian cancer cells overexpressing miR-30 showed significantly (p < 0.05) lower migration and invasion. The miR-30 upregulation also altered the expression pattern of marker proteins of epithelial–mesenchymal transition in ovarian cancer cells. In silico analysis predicted RAB32 as the molecular target of miR-30 at post-transcriptional level. The silencing of RAB32 mimicked the tumor-suppressive effects of miR-30 overexpression in ovarian cancer cells. Nonetheless, overexpression of RAB32 could prevent the tumor-suppressive effects of miR-30 on SK-OV-3 and A2780 cancer cells. Taken together, the results suggest the tumor-suppressive role of miR-30 and point towards the therapeutic utility of miR-30/RAB32 molecular axis in the management of ovarian cancerKeywords
Funding Information
- Shandong Provincial Science and Technology Development Program of Medicine and Health
This publication has 30 references indexed in Scilit:
- Therapeutic Targeting of Long Non-Coding RNAs in CancerTrends in Molecular Medicine, 2018
- EMT in cancerNature Reviews Cancer, 2018
- miR‑30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagyExperimental and Therapeutic Medicine, 2017
- MicroRNA-Directed Cancer Therapies: Implications in Melanoma InterventionThe Journal of pharmacology and experimental therapeutics, 2017
- Ovarian cancerNature Reviews Disease Primers, 2016
- Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinomaClinical & Experimental Metastasis, 2014
- microRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18BMC Cancer, 2014
- Deregulation of Rab and Rab Effector Genes in Bladder CancerPLOS ONE, 2012
- MicroRNA‐30a inhibits epithelial‐to‐mesenchymal transition by targeting Snai1 and is downregulated in non‐small cell lung cancerInternational Journal of Cancer, 2011
- RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomasInternational Journal of Cancer, 2006